AB68-SSA1,1373,22 18(8) Additional responsibilities of commissioner. (a) Application form. The
19commissioner shall make the application form described in sub. (2) (c) 1. a. available
20on the office's Internet site and shall make the form available to pharmacies and
21health care providers who prescribe or dispense insulin, hospital emergency
22departments, urgent care clinics, and community health clinics.
AB68-SSA1,1373,2523 (b) Public outreach. 1. The commissioner shall conduct public outreach to
24create awareness of the urgent need safety net programs and patient assistance
25programs.
AB68-SSA1,1374,2
12. The commissioner shall develop and make available on the office's Internet
2site an information sheet that contains all of the following information:
AB68-SSA1,1374,43 a. A description of how to access insulin through an urgent need safety net
4program.
AB68-SSA1,1374,55 b. A description of how to access insulin through a patient assistance program.
AB68-SSA1,1374,76 c. Information on how to contact a navigator for assistance in accessing insulin
7through an urgent need safety net program or patient assistance program.
AB68-SSA1,1374,98 d. Information on how to contact the commissioner if a manufacturer
9determines that an individual is not eligible for a patient assistance program.
AB68-SSA1,1374,1110 e. A notification that an individual may contact the commissioner for more
11information or assistance in accessing ongoing affordable insulin options.
AB68-SSA1,1374,1812 (c) Navigators. The commissioner shall develop a training program to provide
13navigators with information and the resources necessary to assist individuals in
14accessing appropriate long-term insulin options. The commissioner shall compile
15a list of navigators who have completed the training program and are available to
16assist individuals in accessing affordable insulin coverage options. The list shall be
17made available on the office's Internet site and to pharmacies and health care
18practitioners who dispense and prescribe insulin.
AB68-SSA1,1374,2419 (d) Satisfaction surveys. 1. The commissioner shall develop and conduct a
20satisfaction survey of individuals who have accessed insulin through urgent need
21safety net programs and patient assistance programs. The survey shall ask whether
22the individual is still in need of a long-term solution for affordable insulin and shall
23include questions about the individual's satisfaction with all of the following, if
24applicable:
AB68-SSA1,1374,2525 a. Accessibility to urgent-need insulin.
AB68-SSA1,1375,2
1b. Adequacy of the information sheet and list of navigators received from the
2pharmacy.
AB68-SSA1,1375,33 c. Helpfulness of a navigator.
AB68-SSA1,1375,54 d. Ease of access in applying for a patient assistance program and receiving
5insulin from the pharmacy under the program.
AB68-SSA1,1375,96 2. The commissioner shall develop and conduct a satisfaction survey of
7pharmacies that have dispensed insulin through urgent need safety net programs
8and patient assistance programs. The survey shall include questions about the
9pharmacy's satisfaction with all of the following, if applicable:
AB68-SSA1,1375,1110 a. Timeliness of reimbursement from manufacturers for insulin dispensed by
11the pharmacy under urgent need safety net programs.
AB68-SSA1,1375,1212 b. Ease in submitting insulin orders to manufacturers.
AB68-SSA1,1375,1313 c. Timeliness of receiving insulin orders from manufacturers.
AB68-SSA1,1375,1514 3. The commissioner may contract with a nonprofit entity to develop and
15conduct the surveys under subds. 1. and 2. and to evaluate the survey results.
AB68-SSA1,1375,1816 4. No later than July 1, 2024, the commissioner shall submit to the governor
17and the chief clerk of each house of the legislature, for distribution to the legislature
18under s. 13.172 (2), a report on the results of the surveys under subds. 1. and 2.
AB68-SSA1,1375,23 19(9) Penalty. A manufacturer that fails to comply with this section may be
20assessed a penalty of up to $200,000 per month of noncompliance, with the maximum
21penalty increasing to $400,000 per month if the manufacturer continues to be in
22noncompliance after 6 months and increasing to $600,000 per month if the
23manufacturer continues to be in noncompliance after one year.
AB68-SSA1,3002 24Section 3002 . 632.869 of the statutes is created to read:
AB68-SSA1,1376,2
1632.869 Reimbursement to federal drug pricing program participants.
2 (1) In this section:
AB68-SSA1,1376,63 (a) “Covered entity” means an entity described in 42 USC 256b (a) (4) (A), (D),
4(E), (J), or (N) that participates in the federal drug pricing program under 42 USC
5256b
, a pharmacy of the entity, or a pharmacy contracted with the entity to dispense
6drugs purchased through the federal drug pricing program under 42 USC 256b.
AB68-SSA1,1376,77 (b) “Pharmacy benefit manager” has the meaning given in s. 632.865 (1) (c).
AB68-SSA1,1376,9 8(2) Any person, including a pharmacy benefit manager and 3rd-party payer,
9may not do any of the following:
AB68-SSA1,1376,1210 (a) Reimburse a covered entity for a drug that is subject to an agreement under
1142 USC 256b at a rate lower than that paid for the same drug to pharmacies that are
12not covered entities and are similar in prescription volume to the covered entity.
AB68-SSA1,1376,1513 (b) Assess a covered entity any fee, charge back, or other adjustment on the
14basis of the covered entity's participation in the federal drug pricing program under
1542 USC 256b.
AB68-SSA1,3003 16Section 3003 . 632.87 (4) of the statutes is amended to read: